Kim Van der Eecken

Journal Article
A1
open access

TP53 structure-function relationships in metastatic castrate-sensitive prostate cancer and the impact of APR-246 treatment

Tung Hoang, Philip Sutera, Triet Nguyen, Jinhee Chang, Shreya Jagtap, Yang Song, Amol C. Shetty, Dipanwita D. Chowdhury, Aaron Chan, Francesca A. Carrieri, et al.

(2024) PROSTATE. 84(1). p.87-99

Add to list

Multiregion sampling of de novo metastatic prostate cancer reveals complex polyclonality and augments clinical genotyping

Evan W. Warner, Kim Van der Eecken, Andrew J. Murtha, Edmond M. Kwan, Cameron Herberts, Joonatan Sipola, Sarah W. S. Ng, Xinyi E. Chen, Nicolette M. Fonseca, Elie Ritch, et al.

(2024) NATURE CANCER. 5(1). p.5-7

Add to list

Journal Article
A1
open access

Whole slide imaging-based prediction of TP53 mutations identifies an aggressive disease phenotype in prostate cancer

Marija Pizurica (UGent) , Maarten Larmuseau (UGent) , Kim Van der Eecken, Louise de Schaetzen van Brienen (UGent) , Francisco Carrillo-Perez, Simon Isphording (UGent) , Nicolaas Lumen (UGent) , Jo Van Dorpe (UGent) , Piet Ost (UGent) , Sofie Verbeke (UGent) , et al.

(2023) CANCER RESEARCH. 83(17). p.2970-2984

Add to list

Genomic determinants of patterns of failure in metachronous oligometastatic castration-sensitive prostate cancer

Philip Sutera, Kim Van der Eecken, Amol Shetty, Yang Song, Theresa Hodges, Sofie Verbeke (UGent) , Jo Van Dorpe (UGent) , Valerie Fonteyne (UGent) , Bram De Laere (UGent) , Mark V. Mishra, et al.

(2023) JOURNAL OF CLINICAL ONCOLOGY. In Journal of Clinical Oncology 41(Supplement 6).

Add to list

Overcoming complex polyclonality for accurate clinical genotyping in metastatic prostate cancer

Alexander W. Wyatt, Andrew J. Murtha, Evan Warner, Kim Van der Eecken, Edmond M. Kwan, Cameron Herberts, Joonatan Sipola, Sarah W. S. Ng, Xinyi E. Chen, Nicolette M. Fonseca, et al.

(2023) CANCER RESEARCH. In Cancer Research 83(11, Supplement S).

Add to list

WSI based prediction of TP53 mutations identifies aggressive disease phenotype in prostate cancer

Marija Pizurica (UGent) , Maarten Larmuseau (UGent) , Kim Van der Eecken, Louise de Schaetzen van Brienen (UGent) , Francisco Carrillo-Perez, Simon Isphording, Nicolaas Lumen (UGent) , Jo Van Dorpe (UGent) , Piet Ost (UGent) , Sofie Verbeke (UGent) , et al.

(2023) CANCER RESEARCH. In Cancer Research 83(8, Supplement S).

Add to list

Journal Article
A1
open access

Clinical and genomic differences between advanced molecular imaging-detected and conventional imaging-detected metachronous oligometastatic castration-sensitive prostate cancer

Philip Sutera, Yang Song, Kim Van der Eecken, Amol C Shetty, Keara English, Theresa Hodges, Jinhee Chang, Valerie Fonteyne (UGent) , Zaker Rana, Lei Ren, et al.

(2023) EUROPEAN UROLOGY. 84(6). p.531-535

Add to list

WNT pathway mutations in metachronous oligometastatic castration-sensitive prostate cancer

Philip Sutera, Matthew P. Deek, Kim Van der Eecken, Amol C. Shetty, Jin Hee Chang, Theresa Hodges, Yang Song, Sofie Verbeke (UGent) , Jo Van Dorpe (UGent) , Valerie Fonteyne (UGent) , et al.

(2023) INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS. 115(5). p.1095-1101

Add to list

Multi-focal genomic dissection of synchronous primary and metastatic tissue from de novo metastatic prostate cancer

A. J. Murtha, E. Warner, Kim Van der Eecken, E. Kwan, C. Herberts, J. Sipola, S. Ng, E. Chen, N. Fonseca, E. Schonlau, et al.

(2022) ANNALS OF ONCOLOGY. In Annals of Oncology 33(8, Supplement 8). p.S1384-S1384

Add to list

Genomic features of lung-recurrent hormone-senstive prostate cancer

Nicolette M. Fonseca, Kim Van der Eecken, Cameron Herberts, Sofie Verbeke (UGent) , Sarah W. S. Ng, Nicolaas Lumen (UGent) , Elie Ritch, Andrew J. Murtha, Cecily Q. Bernales, Elena Schonlau, et al.

(2022) JCO PRECISION ONCOLOGY. 6.

Academic Bibliography

Kim Van der Eecken

TP53 structure-function relationships in metastatic castrate-sensitive prostate cancer and the impact of APR-246 treatment

Multiregion sampling of de novo metastatic prostate cancer reveals complex polyclonality and augments clinical genotyping

Whole slide imaging-based prediction of TP53 mutations identifies an aggressive disease phenotype in prostate cancer

Genomic determinants of patterns of failure in metachronous oligometastatic castration-sensitive prostate cancer

Overcoming complex polyclonality for accurate clinical genotyping in metastatic prostate cancer

WSI based prediction of TP53 mutations identifies aggressive disease phenotype in prostate cancer

Clinical and genomic differences between advanced molecular imaging-detected and conventional imaging-detected metachronous oligometastatic castration-sensitive prostate cancer

WNT pathway mutations in metachronous oligometastatic castration-sensitive prostate cancer

Multi-focal genomic dissection of synchronous primary and metastatic tissue from de novo metastatic prostate cancer

Genomic features of lung-recurrent hormone-senstive prostate cancer

Contents

Support

Contact